Anticorps Polyclonal de lapin anti-PD-L1/CD274

• Phare
• Validé par KD/KO

PD-L1/CD274 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA

Conjugaison

Non conjugué

Publications(210)

N° de cat : 17952-1-AP

Synonymes

CD274, PD-L1, B7 H1, B7-H1, hPD-L1

---

Galerie de données de validation

• 

  WB analysis of human placenta using 17952-1-AP

  human placenta tissue were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 17952-1-AP

  Untreated and IFN gamma treated A549 cells were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 17952-1-AP

  Rat kidney tissue was subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 17952-1-AP

  WB result of PD-L1 antibody (17952-1-AP, 1:500) with si-Control and si-PD-L1 transfected HepG2 and HeLa cells.

• 

  WB analysis of mouse heart using 17952-1-AP

  mouse heart tissue were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 17952-1-AP

  Untreated and IFN gamma treated A375 cells were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of K-562 using 17952-1-AP

  K-562 cells were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse skeletal muscle using 17952-1-AP

  mouse skeletal muscle tissue were subjected to SDS PAGE followed by western blot with 17952-1-AP (PD-L1/CD274 Antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IP experiment of mouse heart using 17952-1-AP

  IP result of anti-PD-L1/CD274 (IP:17952-1-AP, 4ug; Detection:66248-1-Ig 1:1000) with mouse heart tissue lysate 4000ug.

• 

  IHC staining of human tonsillitis using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:2000 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:2000 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human stomach cancer using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded human stomach cancer using 17952-1-AP (PD-L1 antibody) at dilution of 1:200 (under 10x lens).

• 

  IHC staining of human stomach cancer using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded human stomach cancer using 17952-1-AP (PD-L1 antibody) at dilution of 1:200 (under 40x lens).

• 

  IHC staining of mouse heart using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse heart tissue slide using 17952-1-AP (PD-L1/CD274 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of mouse heart using 17952-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse heart tissue slide using 17952-1-AP (PD-L1/CD274 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IF Staining of HEK-293 using 17952-1-AP

  Immunofluorescent analysis of HEK-293 cells using 17952-1-AP (PD-L1/CD274 antibody) at dilution of 1:25 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Applications testées

• Résultats positifs en WB: tissu placentaire humain, cellules A375, cellules A549 traitées par IFN gamma, cellules HepG2, cellules K-562, tissu cardiaque de souris, tissu de muscle squelettique de souris, tissu rénal de rat
• Résultats positifs en IP: tissu cardiaque de souris
• Résultats positifs en IHC: tissu d'amygdalite humain, tissu cardiaque de souris, tissu de cancer de l'estomac humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules HEK-293

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:1000-1:4000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 8 publications below
• WB: See 112 publications below
• IHC: See 108 publications below
• IF: See 42 publications below
• IP: See 1 publications below
• CoIP: See 3 publications below
• ChIP: See 1 publications below

Informations sur le produit

17952-1-AP cible PD-L1/CD274 dans les applications de WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: PD-L1/CD274 Protéine recombinante Ag12432
• Nom complet: CD274 molecule
• Masse moléculaire calculée: 290 aa, 33 kDa
• Poids moléculaire observé: 45-56 kDa, 65-70 kDa
• Numéro d’acquisition GenBank: BC074984
• Symbole du gène: PD-L1
• Identification du gène (NCBI): 29126
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).

Publications

Species	Application	Title
human	WB	Nat Biomed Eng; Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.; Authors - Han Yao
human	IHC	Nat Commun; Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1; Authors - Wenfeng Ren
human	WB	Adv Sci (Weinh); BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors; Authors - Shi-Wei Huang
mouse,human	IHC,IF	Acta Pharm Sin B; Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.; Authors - Kuan Hu
human	WB,IHC,IF	Mol Cell; Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.; Authors - Xin Jin
human	WB,IHC,IF	Mol Ther; Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy; Authors - Kang Sun

{{ptg:RelatedPrimaryAntibodies}}